Newsfeeds - Spark Newswire

3 minute read

News

Heat Biologics Announces Planned Name Change To NightHawk Biosciences; Will Trade Under Ticker ‘NHWK’ Effective May 3, 2022

Today, 10:57 AM

Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune

HTBX

1 minute read

Heat Biologics’ Subsidiary Outlines Development of New Commercial/Biodefense Biomanufacturing Facility

By Vandana Singh

Today, 10:57 AM

Heat Biologics Inc (NYSE:HTBX) announced a planned development partnership of its Scorpion Biological Services subsidiary with a private developer, the State of…

HTBX

1 minute read

Heat Biologics’ Announces Planned Investor And Media Livestream Event To Discuss Latest Developments For April 19

By Benzinga Newsdesk

Today, 10:57 AM

Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense

HTBX

1 minute read

Heat Biologics Shares Spike To Session High, Up 8%; Co. Purchased Elusys Therapeutics In Dec. 2021, Elusys’s ANTHIM Was Approved For Treatment Of Inhalation Of Anthrax In US, Canada, Europe, UK

By Benzinga Newsdesk

Today, 10:57 AM

https://ir.heatbio.com/press-releases/detail/706/heat-biologics-announces-planned-acquisition-of-elusys

HTBX

5 minute read

66 Biggest Movers From Yesterday

By Lisa Levin

Today, 10:57 AM

Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 119.5% to settle at $4.39 on Tuesday after the company announced it signed a $60 million sales agreement.

AEHL

1 minute read

Heat Biologics Shares Tick Higher On Volume Following Circulation Of Zack’s Small Cap Research Note Showing $19 Valuation Target On Stock

By Benzinga Newsdesk

Today, 10:57 AM

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Reserach_03172022_HTBX_Vandermosten.pdf

HTBX

2 minute read

Earnings

Heat Biologics’s Return On Capital Employed Overview

By Benzinga Insights

Today, 10:57 AM

Heat Biologics (NASDAQ:HTBX) brought in sales totaling $613.10 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 80.29%, resulting in a loss of $13.61 million.

HTBX

1 minute read

News

Heat Biologics Says Co, Elusys Therapeutics Waived Until March 31 Their Right To Terminate Agreement And Plan Of Merger And Reorganization

By Benzinga Newsdesk

Today, 10:57 AM

-Reuters

HTBX

2 minute read

Heat Biologics Merger Partner Elusys Therapeutics Says Has Finalized Contract With HHS Office Of The Assistant Secretary For Preparedness And Response; Completed First Phase Of Contract For $50M

By Bill Haddad

Today, 10:57 AM

Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an important medical countermeasure in the U.S.

HTBX

10 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 10:57 AM

During Thursday's morning trading, 152 companies set new 52-week lows.

ADTX